← back to search

Scott M. Palmer

Duke University · US
Area of research
Surgery · Pulmonary and Respiratory Medicine
Research interest
Research interests include Transplantation: Methods and Outcomes, Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis, Renal Transplantation Outcomes and Treatments, and Organ Transplantation Techniques and Outcomes.
h-index
80
citations
20,526
works
606
NIH funding
primary concept
email

Recent publications

Circulating metabolic profile in idiopathic pulmonary fibrosis: data from the IPF-PRO Registry
Respiratory Research 2024cited by 24position: middledoi
Prognosis and Risks for Probable Chronic Lung Allograft Dysfunction: A Prospective Multicenter Study
American Journal of Respiratory and Critical Care Medicine 2024cited by 17position: lastdoi
Integrative multi-omics analysis reveals novel idiopathic pulmonary fibrosis endotypes associated with disease progression
Respiratory Research 2023cited by 30position: middledoi
Lung function trajectories in patients with idiopathic pulmonary fibrosis
Respiratory Research 2023cited by 23position: lastdoi
The Impact of Donor Smoking on Primary Graft Dysfunction and Mortality after Lung Transplantation
American Journal of Respiratory and Critical Care Medicine 2023cited by 22position: middledoi
Development and validation of primary graft dysfunction predictive algorithm for lung transplant candidates
The Journal of Heart and Lung Transplantation 2023cited by 11position: middledoi
Additional file 7 of Integrative multi-omics analysis reveals novel idiopathic pulmonary fibrosis endotypes associated with disease progression
Open MIND 2023cited by 0position: middledoi
Additional file 6 of Integrative multi-omics analysis reveals novel idiopathic pulmonary fibrosis endotypes associated with disease progression
Figshare 2023cited by 0position: middledoi
Contemporary trends in PGD incidence, outcomes, and therapies
The Journal of Heart and Lung Transplantation 2022cited by 76position: middledoi
Club Cell Secretory Protein in Lung Disease: Emerging Concepts and Potential Therapeutics
Annual Review of Medicine 2022cited by 61position: lastdoi
Plasma CXCL9 and CXCL10 at allograft injury predict chronic lung allograft dysfunction
American Journal of Transplantation 2022cited by 29position: middledoi
Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA<sub>1</sub>) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD)
BMJ Open Respiratory Research 2021cited by 53position: middledoi
Circulating matrix metalloproteinases and tissue metalloproteinase inhibitors in patients with idiopathic pulmonary fibrosis in the multicenter IPF-PRO Registry cohort
BMC Pulmonary Medicine 2020cited by 101position: middledoi
Risk Factors for Acute Rejection in the First Year after Lung Transplant. A Multicenter Study
American Journal of Respiratory and Critical Care Medicine 2020cited by 73position: middledoi
Liothyronine and Desiccated Thyroid Extract in the Treatment of Hypothyroidism
Thyroid 2020cited by 56position: middledoi
Chronic lung allograft dysfunction: Definition and update of restrictive allograft syndrome―A consensus report from the Pulmonary Council of the ISHLT
The Journal of Heart and Lung Transplantation 2019cited by 295position: middledoi
Peripheral blood proteomic profiling of idiopathic pulmonary fibrosis biomarkers in the multicentre IPF-PRO Registry
Respiratory Research 2019cited by 104position: lastdoi
Predictors of death or lung transplant after a diagnosis of idiopathic pulmonary fibrosis: insights from the IPF-PRO Registry
Respiratory Research 2019cited by 88position: middledoi
Histone Deacetylase 7 Inhibition in a Murine Model of Gram-Negative Pneumonia-Induced Acute Lung Injury
Shock 2019cited by 25position: middledoi
Sensitization in Transplantation: Assessment of Risk (STAR) 2017 Working Group Meeting Report
American Journal of Transplantation 2018cited by 290position: middledoi
Cell-free hemoglobin promotes primary graft dysfunction through oxidative lung endothelial injury
JCI Insight 2018cited by 56position: middledoi
LungMAP: The Molecular Atlas of Lung Development Program
American Journal of Physiology-Lung Cellular and Molecular Physiology 2017cited by 247position: middledoi
Clinical Risk Factors and Prognostic Model for Primary Graft Dysfunction after Lung Transplantation in Patients with Pulmonary Hypertension
Annals of the American Thoracic Society 2017cited by 63position: middledoi
Quantitative Evidence for Revising the Definition of Primary Graft Dysfunction after Lung Transplant
American Journal of Respiratory and Critical Care Medicine 2017cited by 60position: middledoi
High attenuation areas on chest computed tomography in community-dwelling adults: the MESA study
European Respiratory Journal 2016cited by 166position: middledoi
The relationship between plasma lipid peroxidation products and primary graft dysfunction after lung transplantation is modified by donor smoking and reperfusion hyperoxia
The Journal of Heart and Lung Transplantation 2016cited by 31position: middledoi
Redefining Primary Graft Dysfunction after Lung Transplantation
The Journal of Heart and Lung Transplantation 2016cited by 1position: middledoi
Impact of CLAD Phenotype on Survival After Lung Retransplantation: A Multicenter Study
American Journal of Transplantation 2015cited by 121position: middledoi
Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials
The Lancet Respiratory Medicine 2015cited by 85position: middledoi
Objective Estimates Improve Risk Stratification for Primary Graft Dysfunction after Lung Transplantation
American Journal of Transplantation 2015cited by 65position: middledoi

Grants

Lung Transplant Clinical Trial Network (LT-CTN)
NIH3U01AI163099-05S1$297,7302025–2028Contact PIRePORTER
Lung Transplant Consortium - Data Coordinating Center
NIH1U24HL163122-01$2,444,2662022–2027Contact PIRePORTER
Lung Transplant Consortium - Data Coordinating Center
NIH5U24HL163122-02$2,423,5472022–2027Contact PIRePORTER
Lung Transplant Consortium - Data Coordinating Center
NIH5U24HL163122-03$2,367,0332022–2027Contact PIRePORTER
Lung Transplant Consortium - Data Coordinating Center
NIH5U24HL163122-04$2,270,4712022–2027Contact PIRePORTER
Duke Program of Training in Pulmonary ReSearch to Promote, Engage and Retain Academic Researchers (PROSPER)
NIH5T32HL160494-03$606,2332022–2026Contact PIRePORTER
Duke Program of Training in Pulmonary ReSearch to Promote, Engage and Retain Academic Researchers (PROSPER)
NIH1T32HL160494-01$552,6112022–2026PIRePORTER
Duke Program of Training in Pulmonary ReSearch to Promote, Engage and Retain Academic Researchers (PROSPER)
NIH5T32HL160494-02$551,5872022–2026Contact PIRePORTER
Duke Program of Training in Pulmonary ReSearch to Promote, Engage and Retain Academic Researchers (PROSPER)
NIH5T32HL160494-04$438,9972022–2026Contact PIRePORTER
Duke Program of Training in Pulmonary ReSearch to Promote, Engage and Retain Academic Researchers (PROSPER)
NIH5T32HL160494-05$433,4532022–2026Contact PIRePORTER
The IGNITE II CC: Engagement, Coordination, Demonstration, and Dissemination
NIH3U01HG010225-04S2$135,9182022–2023PIRePORTER
Lung Transplant Consortium - Data Coordinating Center
NIH3U24HL163122-04S1$129,6002022–2027Contact PIRePORTER
Lung Transplant Clinical Trial Network (LT-CTN)
NIH5U01AI163099-05$3,897,6432021–2028Contact PIRePORTER
Lung Transplant Clinical Trial Network (LT-CTN)
NIH1U01AI163099-01$2,981,2122021–2028Contact PIRePORTER
Lung Transplant Clinical Trial Network (LT-CTN)
NIH5U01AI163099-02$2,975,3902021–2028Contact PIRePORTER
Lung Transplant Clinical Trial Network (LT-CTN)
NIH5U01AI163099-03$2,973,9902021–2028Contact PIRePORTER
Lung Transplant Clinical Trial Network (LT-CTN)
NIH5U01AI163099-04$1,266,0352021–2028Contact PIRePORTER
Long Term Follow up of the Lung Transplant Outcomes Group Cohort
NIH3U01HL145435-02S1$402,5002020–2022PIRePORTER
Proof of concept treatment interventions in a rodent model of the rare disease bronchiolitis obliterans
NIH1R21TR003037-01A1$241,5002020–2022Contact PIRePORTER
Proof of concept treatment interventions in a rodent model of the rare disease bronchiolitis obliterans
NIH5R21TR003037-02$201,2502020–2022Contact PIRePORTER
Long Term Follow up of the Lung Transplant Outcomes Group Cohort
NIH5U01HL145435-07$1,445,7952019–2027PIRePORTER
Long Term Follow up of the Lung Transplant Outcomes Group Cohort
NIH5U01HL145435-05$1,445,7952019–2026PIRePORTER
Long Term Follow up of the Lung Transplant Outcomes Group Cohort
NIH1U01HL145435-01$1,440,4732019–2026PIRePORTER
Long Term Follow up of the Lung Transplant Outcomes Group Cohort
NIH5U01HL145435-06$1,416,8782019–2026PIRePORTER
Long Term Follow up of the Lung Transplant Outcomes Group Cohort
NIH5U01HL145435-04$1,404,5442019–2026PIRePORTER

Frequent collaborators

Jason D. Christie · KU Leuven16 papers (2012–2018)Lorraine B. Ware · National Heart Lung and Blood Institute16 papers (2012–2018)David J. Lederer · Regeneron (United States)16 papers (2012–2018)M. Crespo · Hospital of the University of Pennsylvania15 papers (2012–2018)Joshua M. Diamond · National Institutes of Health15 papers (2012–2018)Keith Wille · University of Alabama at Birmingham15 papers (2012–2018)Ann Weinacker · Palo Alto University15 papers (2012–2018)Vibha N. Lama · Emory University15 papers (2012–2018)Rupal Shah · University of California, San Francisco14 papers (2012–2017)Jonathan B. Orens · Johns Hopkins University14 papers (2012–2018)Sangeeta Bhorade · Natera (United States)13 papers (2012–2017)Jamie L. Todd · KU Leuven13 papers (2015–2024)Steven M. Kawut · Tufts Medical Center13 papers (2012–2018)Pali D. Shah · Johns Hopkins University12 papers (2012–2024)Edward Cantu · University of Pennsylvania12 papers (2012–2018)Megan L. Neely · University of Alabama at Birmingham11 papers (2019–2024)John A. Belperio · University of California, Los Angeles10 papers (2012–2024)David S. Wilkes · Indiana University10 papers (2012–2017)Selim M. Arcasoy · Columbia University Irving Medical Center8 papers (2012–2017)Scarlett L. Bellamy · Boston University8 papers (2012–2017)